MedPath

Unsaturated Fatty Acids Enriched-diet to Improve Cardiorespiratory Fitness, Metabolic Flexibility and Glucose Tolerance in Obese Patients

Not Applicable
Completed
Conditions
Heart Failure With Normal Ejection Fraction
Obesity
Interventions
Behavioral: Increasing daily unsaturated fatty acid consumption
Registration Number
NCT03310099
Lead Sponsor
Virginia Commonwealth University
Brief Summary

The investigators hypothesize that a dietary intervention aimed at increasing unsaturated fatty acids (UFA) consumption is feasible and has the potential to improve cardiorespiratory fitness, metabolic flexibility and glucose tolerance in symptomatic obese heart failure with preserved ejection fraction (HFpEF) patients.

Detailed Description

Twelve obese HFpEF subjects with exercise intolerance (reduce cardiorespiratory fitness measured at maximal cardiopulmonary exercise test \[CPX\]) will be assigned to a single-arm open-label dietary intervention in which subjects are encouraged and financially supported to increase daily UFA consumption. The investigators will measure dietary compliance with a validated 24-hour dietary recall and with objective operator-independent biomarkers of UFA consumption.

The investigators will also measure the effects of UFA supplementation on: metabolic flexibility, glucose tolerance and body composition. Participants will have the option to participate in overnight session in the whole indirect calorimeter room (WIC) at baseline and at the end of the study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
16
Inclusion Criteria
  • Body Mass Index (BMI) ≥30 kg/m2 (obesity) or total body fat percentage >25% in men and >35% in women
  • A confirmed clinical diagnosis of stable HF (New York Heart Association [NYHA] class II-III) on maximally tolerated heart failure (HF) optimal medical regimen (without major changes in the prior month)
  • Left Ventricular Ejection Fraction (LVEF)>50% documented in the prior 12 months

Major

Read More
Exclusion Criteria
  • Concomitant conditions or treatment which would affect completion or interpretation of the study (i.e.,physical inability to walk or run on treadmill);
  • Significant ischemic heart disease, angina, uncontrolled arterial hypertension, atrial fibrillation, moderate to severe valvular disease, chronic pulmonary disease, anemia (Hemoglobin<10 g/dL)
  • Electrocardiography (ECG) changes (ischemia or arrhythmias) that limit maximum exertion during cardiopulmonary exercise test
  • Comorbidity limiting survival
  • Stage IV-V kidney disease (estimated Glomerular Filtration Rate<30)
  • Fluid overload
  • Pregnancy
  • Current use of unsaturated fatty acids (UFA) supplement (i.e., omega-3).
  • Inability to give informed consent
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Dietary InterventionIncreasing daily unsaturated fatty acid consumptionDietary intervention aimed at increasing UFA consumption. The face-to-face intervention will be performed by a research nutritionist that reviews the dietary recall and provides a list of commonly available foods rich in unsaturated fatty acids (UFA) (monounsaturated \[MUFA\] and polyunsaturated fatty acids \[PUFA\]), together with individual instructions on how to integrate the recommended foods in the daily dietary pattern based on the dietary recall, and also to emphasize that the recommended food should be consumed as listed, and not as part of processed food (i.e., guacamole for avocado, hazelnut chocolate for nuts, pesto for olive oil, fish sticks for fatty fish). Extra-virgin olive oil or canola oil or nuts will be considered first choice for daily consumption of UFA-rich food, but a list of daily food substitutes will be also provided .
Primary Outcome Measures
NameTimeMethod
Change in dietary compliance (biomarkers)Baseline to 12 weeks

Measured by changes in biomarkers of unsaturated fatty acid consumption

Change in 24-hour dietary recallBaseline to 12 weeks

Measured with validated 24-hour dietary recall (non-self administered)

Secondary Outcome Measures
NameTimeMethod
Change in body compositionAt baseline and at 12 weeks

Assessed by dual energy X-ray absorptiometry (DXA)

Change in metabolic flexibilityAt baseline and 12 weeks

Area under the curve change of respiratory quotient measured during overnight stay for 14 hours in the WIC

Change in glucose toleranceAt baseline and at 12 weeks

Oral glucose tolerance test (OGTT) measures plasma glucose and insulin

Trial Locations

Locations (1)

Virginia Commonwealth University

🇺🇸

Richmond, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath